A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)
at end of study
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CBEZ235A2101
NCT00620594
December 2006
January 2013
Name | Location |
---|---|
Cancer Centers of the Carolinas CCC Faris | Greenville, South Carolina 29605 |
MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med.Onc(2) | Houston, Texas 77030-4009 |
University of California at Los Angeles JonssonComprehensiveCancerCtr | Los Angeles, California 90095 |
Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice | New Haven, Connecticut 06520 |
Dana Farber Cancer Institute Clinical Trials ProjectManager | Boston, Massachusetts 02115 |
Nevada Cancer Institute NVCC - Huntsman | Las Vegas, Nevada 89135 |
Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2) | Nashville, Tennessee 37203 |
Baylor College of Medicine Baylor- Sammons | Dallas, Texas 75246 |
Tyler Cancer Center TCC | Tyler, Texas 75702 |